[ad_1]
The results of two studies of the Russian corona vaccine “Sputnik V” are published today in The Lancet.
A total of 76 people participated in the studies, a phase 1 and a phase 2. More than half of the participants in phase 1 and all in the phase 2 study developed antibodies within three weeks, the researchers write. No serious side effects were seen in 42 days.
The results also indicate that the vaccine also causes the patient to develop so-called T cells within 28 days.
The researchers emphasize that more studies are needed, both in duration and in number of participants, to be able to ensure the effectiveness and safety of the vaccine over time.
Duplicate studies
The studies were conducted in two Moscow hospitals, with 76 healthy participants aged 18 to 60 years. In one study, the participants were civilians and military, in the other civilian.
All participants knew they were receiving the vaccine and no placebo was included.
About half of all participants experienced injection site pain, fever, and headache within 42 days.
The researchers write that these side effects were mild and that they are common even when other types of vaccines are given.
Now a phase 3 study will be conducted, with 40,000 participants that will also include people in risk groups, reports The Lancet.
Swedish Vaccine Coordinator: Here’s How Vaccination Should Go
The vaccination coordinator wants to access the vaccine as soon as possible.
